MPTENs as modifiers of the PTEN/IGF pathway and methods of use

Details for Australian Patent Application No. 2004253863 (hide)

Owner Exelixis, Inc.

Inventors Ollmann, Michael Martin; Zhang, HaiGuang; Song, Chunyan; Lickteig, Kim; Bjerke, Lynn Margaret

Agent Davies Collison Cave

Pub. Number AU-A-2004253863

PCT Pub. Number WO2005/003297

Priority 60/470,766 14.05.03 US

Filing date 13 May 2004

Wipo publication date 13 January 2005

International Classifications

C12N 005/00 Undifferentiated human, animal or plant cells, e.g. cell lines

C12Q 001/68 Measuring or testing processes involving enzymes or micro-organisms - involving nucleic acids

Event Publications

10 November 2005 PCT application entered the National Phase

  PCT publication WO2005/003297 Priority application(s): WO2005/003297

10 December 2009 Application Lapsed, Refused Or Withdrawn, Patent Ceased or Expired

  This application lapsed under section 142(2)(d). Examination has been requested or an examination report has issued for this application. Note that applications or patents shown as lapsed or ceased may be restored at a later date.

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2004253865-Surrogate therapeutic endpoint for antiCTLA-4 based immunotherapy of disease

2004253862-Methods and compositions for maturing dendritic cells utilizing inosine-containing compounds